ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial

Rákkutatás · Ovarian cancer

ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial

In a multi‑institutional randomized clinical trial (NCT03949283), 81 patients with recurrent platinum‑resistant epithelial ovarian cancer were randomized 1:1 to receive either ChemoID‑guided chemotherapy or best physician‑choice chemotherapy. ChemoID is a functional assay that screens standard‑of‑care chemotherapies on patient‑derived tumor cells and cancer‑stem‑cell populations to predict cytotoxic efficacy. The primary endpoint was objective response rate (ORR) assessed by RECIST 1.1 at 6 months. ORR was 55 % (95 % CI 39–73 %) in the ChemoID arm versus 5 % (95 % CI 0–11 %) in the physician‑choice arm (p < 0.0001). Secondary endpoints included median progression‑free survival (11.0 mo vs 3.0 mo, HR 0.27, p < 0.001), duration of response (8 mo vs 5.5 mo), and clinical benefit rate. The trial was stopped early after the first interim analysis due to meeting efficacy criteria.

Recurrent platinum‑resistant ovarian cancer has dismal prognosis and limited therapeutic options. Demonstrating that a precision‑medicine assay can identify more effective chemotherapy regimens and substantially improve response rates offers a clinically meaningful advancement that could reshape standard care for this high‑mortality disease.

Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.

Eredeti forrás

Kapcsolódó jelek